Duration of residency in a non-endemic area and risk of severe malaria in African immigrants  by Färnert, A. et al.
ORIGINAL ARTICLE PARASITOLOGYDuration of residency in a non-endemic area and risk of severe malaria in
African immigrantsA. Färnert1,2, K. Wyss2,3, S. Dashti2 and P. Naucler1,2
1) Department of Infectious Diseases, Karolinska University Hospital, 2) Infectious Diseases Unit, Department of Medicine Solna, Karolinska
Institutet and 3) Department of Emergency Medicine, Karolinska University Hospital, Stockholm, SwedenAbstractIn malaria-endemic areas, adults very rarely succumb to severe malaria, suggesting that immunity to severe disease is life-long under conditions
of repeated exposure. To what extent this protection persists in the absence of exposure remains to be established. The aim of this study was to
assess whether duration of residency in a malaria-free country affects the risk for severe malaria in immigrants originating from sub-Saharan
Africa. We conducted a retrospective chart review of 948 cases of malaria diagnosed in Stockholm, Sweden in 1995–2013. Among 501 adult
patients with Plasmodium falciparum (315 of endemic origin and 186 of non-endemic origin, mainly Sweden), 41 (8.2%) had severe malaria
according to WHO criteria (including 5% with parasitaemia), 22 (4.4%) had factors prognostic of poor outcome, and 35 (7.0%) were
admitted to intensive care. Overall, patient origin did not affect the odds of severe malaria, according to any of these deﬁnitions. However,
when the immigrants were stratiﬁed with regard to their duration of residency in Sweden, the risk of factors prognostic for poor outcome
was associated with duration of prior residency in a malaria-free country among patients of endemic origin (p 0.02), and immigrants who
had lived for 15 years in Sweden had a similar risk as non-immune travellers. The results of this explorative study suggest that, although
immunity to severe malaria is maintained for several years in African adults, this protection might be lost with time without repeated re-
exposure. A larger study, preferably including multiple centres, will be needed to conﬁrm our ﬁndings.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: anna.farnert@ki.seIntroductionMalaria is a potentially life-threatening infection in non-immune
individuals [1]. In highly endemic areas, most of which are in
sub-Saharan Africa, severe Plasmodium falciparum malaria affects
mainly young children, before they gradually acquire clinical
protection after repeated infections. In areas of lowerMicrobiol Infect 2015; 21: 494–501
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endemic areas, individuals of all ages are at risk for severe
malaria.
Acquired immunity tends to lower the occurrence of severe
malaria faster than that of uncomplicated disease [2]. The low
incidence of severe malaria in older children and adults in high-
transmission settings suggests that this immunity is life-long
under conditions of repeated exposure. However, whether
protective immunity to severe malaria is maintained in the
absence of re-exposure is debated, with some suggesting that
this protection wanes rapidly [2] and others that it persists [3].
Understanding the longevity of immunity against malaria is
important for the development of efﬁcacious vaccines and for
predictions of populations at risk in areas of changing
transmission.European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
CMI Färnert et al. Severe malaria and duration of residency in non-endemic areas 495Immigrants originating from malaria-endemic areas in sub-
Saharan Africa and living in malaria-free countries, e.g. in
Europe, are at high risk of malaria when returning to malarious
areas [4]. Nonetheless, African immigrants are generally
recognized to be at lower risk of severe forms of the disease
than non-immune travellers [5–10]. To what extent this pro-
tection wanes with time when people are living in non-endemic
areas has not been reported.
We conducted a retrospective chart review of malaria cases
diagnosed in Stockholm, Sweden, with the aim of assessing
whether the risk of severe malaria in African immigrants is
affected by the duration of residency in a malaria-free country.MethodsThe study was approved by the Regional Ethical Review Board,
Stockholm, Sweden (Drnr 2009/1328-31/5, 2010/1080-32,
2012/1150-32).
Study population
We sought to include all patients diagnosed with malaria in
Stockholm, Sweden, between January 1995 and May 2013.
Completeness of data was evaluated through comparison with
surveillance data at the Public Health Agency of Sweden. The
patients were treated at the ﬁve hospitals in Stockholm with de-
partments of infectious diseases. The analyses included patients
aged 16 years with symptomatic P. falciparum malaria and
complete clinical records, and with an origin in sub-Saharan Africa
or malaria-free countries. Only the ﬁrst malaria episode was
included for patients with multiple episodes. Patients originating
fromAsia and other areaswith lower transmissionwere excluded.
Malaria diagnosis
Malaria was diagnosed by microscopy of thick and thin blood
ﬁlms stained with Field’s stain. The parasite species was
determined in thin ﬁlms, and occasionally by PCR. Parasitaemia
was deﬁned as percentage of infected erythrocytes in thin
smears.
Clinical and demographic data
Medical records were reviewed regarding demographics, travel
history (including chemoprophylaxis), clinical presentation
(signs and laboratory tests), management (admission to hospital
and treatment), and disease outcome.
Severe malaria was deﬁned according to: (a) WHO criteria,
including 5% cut-offs for hyperparasitaemia [11,12]; (b) factors
with higher prognostic value for poor outcome [11]); and (c)
admission to the intensive-care unit (ICU). The WHO criteria
included at least one of the following: impaired consciousnessClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artior unrousable coma (Glasgow Coma Scale 10 (adjusted from
[13,14]), multiple convulsions, pulmonary oedema, respiratory
distress, circulatory collapse (systolic blood pressure of
70 mmHg), abnormal spontaneous bleeding, macroscopic
haemoglobinuria, hypoglycaemia (blood glucose level of
<2.2 mmol/L), renal failure (serum creatinine level of
>265 μmol/L), severe anaemia (haemoglobin level of <5 g/dL),
acidosis (pH of <7.25, plasma bicarbonate level of <15 mmol/L,
base excess of <10, hyperlactataemia, i.e. lactate level of
>5 mmol/L, or when stated in the medical record if laboratory
data were missing), and jaundice (bilirubin level of >50 μmol/L)
together with evidence of other vital organ dysfunction. Factors
with higher prognostic value for poor outcome included
impaired consciousness, acidosis, multiple convulsions, circula-
tory collapse, pulmonary oedema, and/or abnormal bleeding.
Statistical analyses
Analyses were performed with STATA 11.0. The risk of severe
malaria was assessed in relation to (a) origin in a malaria-
endemic country in sub-Saharan Africa, and (b) years of resi-
dency in a malaria-free country (including immigrants living for
>1 year in Sweden). Chi-squared tests and Fisher’s tests were
used for categorical variables, the Mann–Whitney U-test for
continuous variables, logistic regression for binary outcomes,
and linear regression for continuous outcomes. Multivariate
modelling was performed to adjust for sex and age, and also
chemoprophylaxis usage and patient delay (number of days of
symptoms before seeking care).ResultsWe identiﬁed 948 microbiologically conﬁrmed cases of malaria
in Stockholm in 1995–2013, corresponding to 97.8% of cases
notiﬁed to the Public Health Agency of Sweden. In total, 632
P. falciparum episodes were diagnosed in 601 patients (Fig. 1),
and 501 symptomatic adults were included in the analyses: 186
patients from non-endemic countries (87.1% from Sweden) and
315 patients originating from endemic countries in sub-Saharan
Africa (54.8% from West Africa and 36.5% from East Africa,
respectively) (Table 1).
Among the African immigrants, 39.4% had resided for >10
years in Sweden, and 18.0% had spent <1 year in Sweden
(15.8% for <1 month), including temporary visitors and newly
arrived migrants, when diagnosed with malaria (Table 1). The
majority of immigrants (93.0%) had lived for >10 years in a
malaria-endemic country before moving to Sweden. All immi-
grants, and 87.7% of travellers from non-endemic countries,
had visited African countries prior to infection, and 92.1% of
the immigrants had visited their countries of origin (Table 1).of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 494–501
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FIG. 1. The analyses included pa-
tients with P. falciparum malaria who
were aged >16 years and originated
either from a non-endemic area
(mainly Sweden) or malaria-endemic
countries in sub-Saharan Africa
(grey boxes). The study population
was selected among all patients
diagnosed with malaria in Stockholm,
Sweden, between January 1995 and
May 2013.
496 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIAfrican immigrants were younger, were predominantly male,
had lower usage of antimalarial chemoprophylaxis and had a
longer time from symptom onset to seeking healthcare than
patients from non-endemic areas (all p  0.01) (Table 1).
Severe malaria according to WHO criteria was found in 41
(8.2%) patients, 22 (4.4%) had factors prognostic of poor
outcome, and 35 (7.0%) were admitted to ICUs. All cases with
factors prognostic for poor outcome were included within the
WHO criteria 5% deﬁnition. Eight patients were admitted to
ICUs without fulﬁlling the WHO criteria 5% deﬁnition.
Severity of disease with regard to patient origin and
time spent in non-endemic areas
An overall comparison between African immigrants and patients
of non-endemic origin did not reveal any signiﬁcant differences in
the odds of severe malaria according to any of the deﬁnitions, in
either unadjusted or adjusted analyses (adjusting for sex and age,
and for intake of chemoprophylaxis and patient delay) (Table 2).
When the immigrants were stratiﬁed with regard to years of
residency in a malaria-free country, severe malaria was, overall,
less frequent in immigrants who had lived for <10 years in Sweden
(Fig. 2(a) and (c)). Immigrants who had lived in Sweden for 10–14
years and 15 years were similar to travellers of non-endemic
origin with regard to severe malaria deﬁned according to
WHO criteria (9.7% and 10.0% vs. 9.5%) (Fig. 2(a)). Also,
admission to ICUs was similar in immigrants who had lived in
Sweden for 15 years (9.5%) and patients with non-endemic
origin (9.7%) (Fig. 2(c)). The effect of years of residency on ICU
admission and WHO criteria did not, however, reach statisticalClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licesigniﬁcance (all p > 0.05). Interestingly, duration of residency in a
malaria-free country was signiﬁcantly associated with the most
severe forms ofmalaria, i.e. factors prognostic for poor outcomes
(p 0.02). Immigrants who had lived in Sweden for15 years had a
similar proportion of severe signs as Swedish travellers and other
patients from non-endemic areas (8.1% and 6.5%, respectively)
(Fig. 2(b)). In contrast, none of the immigrants who had lived in
Sweden for 5–14 years had any of these signs, and among patients
who has immigrated more recently, four had severe malaria.
Unarousable coma was diagnosed in eight patients: four patients
of non-endemic origin and four of endemic origin. Three of these
had lived in Sweden for 17, 20 and 30 years, and one was a
pregnant temporary visitor. There were no in-hospital deaths.
The risk of severe malaria increased gradually after age 40
years in patients from both areas (endemic, p 0.02; non-
endemic, p 0.05) (Table 3). Nonetheless, African immigrants
with severe malaria were younger (median, 42 years; range,
21–53 years) than severely ill patients of non-endemic origin
(median, 52 years; range, 31–74 years). Chemoprophylaxis
usage and patient delay were not associated with severity of
disease or ICU admission (all p > 0.15) (Table 3).
Patients from non-endemic areas were more often admitted
to hospital (92.5% vs. 79.7%, p < 0.001), had longer hospital
stays (mean, 3.92 days; 1.72 days longer; unadjusted 95% CI
1.10–2.35) and were more often given intravenous treatment
(28.5% vs. 19.7%, p 0.03) than immigrant patients. Nonetheless,
when severity of disease was included in an adjusted model,
these differences remained, indicating that they were not
explained by disease severity (data not shown).European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 494–501
nses/by-nc-nd/4.0/)
TABLE 1. Characteristics among adult patients diagnosed
with Plasmodium falciparum malaria in Stockholm, Sweden,
according to patient origin from a malaria-endemic country
Endemic origin
(N [ 315), n (%)
Non-endemic origin
(N [ 186), n (%) p
Age (years)
Median 36.5 38.1 <0.001
<40 209 (66.3) 95 (51.1) <0.001
40–49.99 78 (24.8) 33 (17.7)
50–59.99 23 (7.3) 42 (22.6)
60 5 (1.6) 16 (8.6)
Male sex 222 (70.5) 111 (59.7) 0.01
Patient origina
East Africa 115 (36.5) 0
Central Africa 25 (7.9) 0
Southern Africa 2 (0.6) 0
West Africa 173 (54.9) 0
South America 0 1 (0.5)
North America 0 3 (1.6)
Western Asia 0 1 (0.5)
Southern Asia 0 0
Europe 0 180 (96.8)
Oceania 0 1 (0.5)
Region visiteda
East Africa 111 (35.2) 80 (43.0)
Central Africa 26 (8.3) 9 (4.8)
Southern Africa 1 (0.3) 3 (1.6)
West Africa 177 (56.2) 71 (38.2)
South America 0 3 (1.6)
Southern Asia 0 3 (1.6)
Southeast Asia 0 14 (7.5)
Western Asia 0 1 (0.5)
Missing 0 2 (1.1)
Accumulated time living in non-endemic area (years)
<1 57 (18.1) 0
1–2 12 (3.8) 0
3–4 40 (12.7) 0
5–9 67 (21.3) 0
10–14 50 (15.9) 0
15 74 (23.5) 186 (100)
Missing 15 (4.8) 0
Accumulated time living in endemic area
<6 months 0 147 (79.0)
6–12 months 0 14 (7.5)
1–4 years 1 (0.3) 10 (5.4)
5–9 years 6 (1.9) 9 (4.8)
10 years 293 (93.0) 5 (2.7)
Missing 15 (4.8) 1 (0.5)
Use of malaria prophylaxis
Regular 19 (6.0) 60 (32.3) <0.001
Irregular/none 241 (76.5) 115 (61.8)
Missing 55 (17.5) 11 (5.9)
Patient delay (days)b
0–1 52 (16.5) 67 (36.0) <0.001
2–3 127 (40.3) 64 (34.4)
4–5 74 (23.5) 25 (13.4)
>5 60 (19.1) 30 (16.1)
Missing 2 (0.6) 0
aCountries according to UN geoscheme [15]. Included countries: East Africa
(Burundi, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda,
Somalia, Sudan, Tanzania, Uganda, Zambia, and Zimbabwe); Central Africa (Angola,
Cameroon, and Democratic Republic of Congo); southern Africa (Namibia and
South Africa); West Africa (Benin, Burkina Faso, Gambia, Ghana, Guinea, Guinea-
Bissau, Ivory Coast, Liberia, Mali, Nigeria, Senegal, Sierra Leone, and Togo); South
America (Chile); North America (USA); western Asia (Lebanon and Yemen);
southern Asia (India); Southeast Asia (Thailand and Indonesia); and Oceania
(Australia). European countries are combined. Missing: 2 patients were infected in
Africa but the country was not speciﬁed.
bTime from symptom onset to seeking healthcare
CMI Färnert et al. Severe malaria and duration of residency in non-endemic areas 497DiscussionSevere P. falciparum malaria is widely reported to be less
frequent in immigrants from sub-Saharan Africa than in non-
immune travellers [5–10]; however some authors have not
found such differences [16]. Here, using strict deﬁnitions of
severity, we did not detect any signiﬁcant overall differences inClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf
This is an open access artisevere malaria between these groups. However, when the
immigrants were stratiﬁed with regard to duration of residency
in Sweden, we found an effect of duration on the most severe
forms of malaria. The results suggest that, although immunity to
severe malaria is maintained for several years, this protection
might be lost without repeated re-exposure.
We compared individuals from sub-Saharan Africa, where
P. falciparum malaria is highly endemic, with travellers from
Sweden or other malaria-free countries. Country of origin is, of
course, a crude marker of malaria exposure and pre-existing
immunity, and transmission intensity often varies greatly
within countries [1]. African immigrants who have lived in
Sweden for only a few years are likely to represent the back-
ground level of immunity in the heterogeneous population with
different histories of exposure. Only a few cases of severe
malaria were recorded among immigrants residing for between
1 and 10 years in Sweden, and although various patterns were
noted, the majority of severe cases were recorded in patients
with longer residency.
Numerous studies have compared immigrants and non-
immune travellers, with different designs and deﬁnitions of se-
vere malaria. Bouchaud et al. described a lower risk of severe
malaria in immigrants living in France for a median of 14 years;
however, severity of disease was not reported in relation to the
number of years in a malaria-free country [6]. Another study
performed over different periods reported severe malaria only
in immigrants residing for 13–19 years in Italy [17]. A high risk
of severe malaria has also been reported in newly arrived mi-
grants (mainly severe anaemia) [8]. Also, in our study some
severe signs of malaria were detected in newly arrived Africans,
perhaps because of factors related to recent migration. The
analysis of severity in relation to time of residency was there-
fore restricted to immigrants who had lived for at least 1 year in
Sweden.
The risk of severe malaria was assessed according to
different deﬁnitions. With the WHO criteria, including a 5%
threshold for hyperparasitaemia, we found a tendency for
there to be more severe malaria in immigrants who had lived
in Sweden for >10 years. The parasitaemia 5% threshold does
not, however, always correlate with severity [18], and
hyperparasitaemia is no longer stated as an individual param-
eter in the recently updated WHO guidelines for management
of severe malaria [19]. Admission to an ICU undoubtedly re-
ﬂects severe disease; however, the criteria for ICU admission
might have varied in different hospitals and over time. We
therefore considered factors prognostic for poor outcome to
constitute the most robust marker of severe malaria. Although
restrictive, this deﬁnition of outright complicated malaria best
predicted an increased risk of severe malaria in long-term
residents.of European Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 494–501
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 2. Severity of Plasmodium falciparum malaria with regard to patient origin
Severe malaria deﬁnition
Endemic
(N [ 315), n (%)
Non-endemic
(N [ 186), n (%)
OR (95% CI)
Un-adjusted Adjusted model 1a Adjusted model 2b
WHO criteria 5%c,d 23 (7.3) 18 (9.7) 1.36 (0.71–2.59) 1.02 (0.50–2.07) 0.89 (0.40–1.96)
Factors prognostic of poor outcome 10 (3.2) 12 (6.5) 2.10 (0.89–4.97) 1.33 (0.52–3.43) 1.12 (0.40–3.16)
ICU admission 17 (5.4) 18 (9.7) 1.88 (0.95–3.75) 1.49 (0.70–3.15) 1.28 (0.56–2.90)
ICU, intensive-care unit.
aModel 1. Adjusted for sex and age. Based on 501 study subjects.
bModel 2. Adjusted for sex, age, prophylaxis and patient delay. Based on 433 study subjects with complete data.
cAccording to WHO deﬁnition.
dHyperparasitaemia deﬁned as >5%.
498 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIMoreover, frequency of admission to hospital, frequency of
intravenous treatment and length of hospital stay were all lower
in African immigrants; however, not all of these were explained
by severity of disease. Differences in length of hospital stay
might reﬂect faster clearance of symptoms [6], but might also
represent the patient’s own desire not to stay in the hospital or
the physician’s fear of more severe disease in non-immune
travellers. These factors are thus not as stringent predictors
of severity as speciﬁc clinical signs.
Fatal outcome is obviously the most severe marker of dis-
ease. Interestingly, no deaths were recorded among patients
diagnosed with malaria in Stockholm in 1995–2013. The case-
fatality rates in patients with P. falciparum malaria in non-
endemic areas have been reported to be 0.3–1.3% overall
[5,7,20,21], 0–0.9% in immigrants (reviewed in [22]), and
0.6–3% in non-immune travellers [7,20]. The case-fatality rate
was substantially higher in areas in the UK where malaria
diagnosis was uncommon [20], and doctors’ delay was reported
in fatal cases in Switzerland [23]. In Stockholm, the acute
management of fever in patients returning from tropical areas is
centralized to specialist physicians in infectious diseases with
prompt access to malaria diagnostics and care, which might
have contributed to the favourable outcome.
Old age has been identiﬁed as a risk factor for severe malaria in
travellers [24,25]. Gradually increased risk with age after 40 years
was observed, irrespective of origin. The immigrants with severe
malaria were younger than the Swedish travellers also reﬂected by
different age proﬁles in the two groups (Table 1). Adjustments for
age were not possible within the respective strata for duration of
residency, and a larger study would be needed for more detailed
analyses of age in relation to time without re-exposure.
Host genetic factors, including sickle-cell traits and other
haemoglobinopathies, are common in African populations, and
may explain the reduced risk for severe malaria in the immi-
grant group [9]. Although genetic factors are likely to
contribute to protection, they could not explain the changing
risk with time in immigrants observed in our study.
An understanding of the mechanisms by which immunity to
severe malaria is acquired and maintained would be highlyClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licevaluable for vaccine development. Antibodies are well recog-
nized to constitute an important component of malaria immu-
nity; however, antibodies against P. falciparum antigens have
been reported to be short-lived [26]. There is now growing
evidence that, despite a lack of circulating antibodies,
P. falciparum-speciﬁc memory B-cells are also long-lived in
travellers [27], and higher antibody levels after an episode of
acute malaria in immigrants suggest activation of immunological
memory [6]. Further studies are needed to identify the immune
responses involved in immunity to severe malaria in relation to
longevity of protection.
The changing epidemiology over the last decade has resulted
in targets being set for malaria elimination in several countries
[1]. Reducing transmission might change the age patterns of
infections, with older children being at risk for severe malaria
[28]. Moreover, formerly immune individuals might lose im-
munity, unless they are repeatedly infected or chronically
parasitized [29]. In the highlands of Madagascar, where malaria
re-emerged after efﬁcacious control for 30 years, older adults
were less likely to contract malaria (severity not reported) [30].
The longevity of immunity against severe malaria has, to our
knowledge, not been reported in epidemiological studies, and
we believe that the approach of studying travellers can
contribute valuable information.
Limitations of the study are inherent in the retrospective
study design; for eaxmple, reliable information about the
frequency of visits to malarious areas was not available. Sys-
tematic collection of data in a prospective study is preferable;
such a study would not, however, be possible in a single
centre such as Stockholm. Although we included all cases of
malaria over nearly two decades, the number of cases
restricted in-depth subgroup analyses with regard to years
without exposure. A larger study, preferably including multi-
ple centres, will be needed to conﬁrm the validity of our
ﬁndings.
In conclusion, the results from this explorative study indicate
that the risk of severe malaria in African immigrants is affected
by duration of residency in a malaria-free country. If conﬁrmed,
the ﬁndings challenge the notion that immunity to severeEuropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 494–501
nses/by-nc-nd/4.0/)
FIG. 2. The proportion of immi-
grants with severe malaria increases
with years of residency in a malaria-
free country. Severe malaria was
deﬁned according to: (a) WHO
criteria, including hyperparasitaemia
>5%; (b) factors prognostic for poor
outcome (deﬁned in Methods); and
(c) intensive-care unit (ICU) admis-
sion. Absolute numbers are pre-
sented above bars within brackets.
Comparison of years in a non-
endemic country by the use of chi-
squared or Fisher’s test as appro-
priate, and comparison of 1–4, 5–9,
10–14 and 14 years, respectively,
demonstrates overall differences be-
tween these four groups. p-values:
(a) 0.57, (b) 0.02, and (c) 0.33.
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TABLE 3. Severity of Plasmodium falciparum malaria in relation to patient characteristics
Total no.
WHO criteriaa Factor prognostic of poor outcomeb ICU admission
Positive, n (%) OR (95% CI) Positive, n (%) OR (95% CI) Positive, n (%) OR (95% CI)
Age (years)
<40 304 14 (4.6) 1 (ref.) 6 (2.0) 1 (ref.) 12 (4.0) 1 (ref.)
40–49.99 111 13 (11.7) 2.75 (1.25–6.05) 6 (5.4) 2.84 (0.90–8.99) 11 (9.9) 2.68 (1.15–6.26)
50–59.99 65 9 (13.9) 3.33 (1.37–8.07) 7 (10.8) 5.99 (1.94–18.48) 8 (12.3) 3.42 (1.34–8.73)
60 21 5 (23.8) 6.47 (2.07–20.21) 3 (14.3) 8.28 (1.91–35.83) 4 (19.1) 5.73 (1.67–19.64)
Sex
Female 168 14 (8.3) 1 (ref.) 10 (6.0) 1 (ref.) 13 (7.7) 1 (ref.)
Male 333 27 (8.1) 0.97 (0.49–1.90) 12 (3.6) 0.59 (0.25–1.40) 22 (6.6) 0.84 (0.41–1.72)
Accumulated time in endemic area
<6 months 147 15 (10.2) 1 (ref.) 9 (6.1) 1 (ref.) 14 (9.5) 1 (ref.)
6–12 months 14 1 (7.1) 0.68 (0.08–5.54) 1 (7.1) 1.18 (0.14–10.05) 1 (7.1) 0.73 (0.09–6.01)
1–4 years 11 1 (9.1) 0.88 (0.11–7.36) 1 (9.1) 1.53 (0.18–13.34) 2 (18.2) 2.11 (0.41–10.75)
5–9 years 15 1 (6.7) 0.63 (0.08–5.12) 1 (6.7) 1.10 (0.13–9.29) 1 (6.7) 0.68 (0.08–5.55)
10 years 298 23 (7.7) 0.74 (0.37–1.46) 10 (3.4) 0.53 (0.21–1.34) 17 (5.7) 0.57 (0.27–1.20)
Missing 16 0 (0) 0 (0) 0 (0)
Use of malaria prophylaxis
Regular 79 9 (11.4) 1 (ref.) 6 (7.6) 1 (ref.) 8 (10.1) 1 (ref.)
Irregular/none 356 30 (8.4) 0.72 (0.33–1.57) 16 (4.5) 0.57 (0.22–1.51) 26 (7.3) 0.70 (0.31–1.61)
Missing 66 3 (3.0) 0 (0)
Patient delay (days)
0–1 119 9 (7.6) 1 (ref.) 5 (4.2) 1 (ref.) 6 (5.0) 1 (ref.)
2–3 191 14 (7.3) 0.97 (0.40–2.31) 7 (3.7) 0.87 (0.27–2.80) 11 (5.8) 1.15 (0.41–3.20)
4–5 99 9 (9.1) 1.22 (0.47–3.21) 5 (5.1) 1.21 (0.34–4.32) 9 (9.1) 1.88 (0.65–5.49)
>5 90 9 (10.0) 1.36 (0.52–3.57) 5 (5.6) 1.34 (0.38–4.78) 9 (10.0) 2.09 (0.72–6.11)
Missing 2 0 (0) 0 (0) 0 (0)
aAccording to WHO deﬁnition, including hyperparasitaemia >5%.
bDeﬁned as the presence of impaired consciousness, acidosis, circulatory collapse, convulsions, pulmonary oedema, and/or abnormal bleeding.
500 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMImalaria is life-long without re-exposure, and identiﬁes a group
of patients who might deserve special attention in the man-
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